Bristol-Myers Squibb Company (BMY) vs Gilead Sciences, Inc. (GILD)
A side-by-side comparison of Bristol-Myers Squibb Company and Gilead Sciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 29, 2026. Differences are shown without an overall score or investment verdict.
BMY
Bristol-Myers Squibb Company
$63.43HealthcareDelayed quote: Jul 29, 2026, 3:35 PM EDT
GILD
Gilead Sciences, Inc.
$133.27HealthcareDelayed quote: Jul 29, 2026, 3:35 PM EDT
Total return — BMY vs GILD
growth of $100 · dividends reinvested · last 30yBMY +783.7%GILD +33309.9%GILD compounded faster
Log scale — wide-divergence pair
BMY GILD
BMY vs GILD: by the numbers
- •GILD is the larger company ($165.46B vs $129.53B market cap).
- •BMY trades at the lower trailing earnings multiple (17.87 vs 18.30 P/E), one valuation lens rather than an overall verdict.
- •GILD converts more revenue to profit (30.99% vs 15.01% net margin).
- •GILD grew revenue faster over the past five years (3.07% vs 2.52% CAGR).
- •BMY pays the higher dividend yield (3.93% vs 2.40%).
Metrics side by side
Valuation
| Metric | BMY | GILD |
|---|---|---|
| P/E ratio | 17.87 | 18.30 |
| Forward P/E | 10.02 | N/A |
| P/S ratio | 2.68 | 5.66 |
| P/B ratio | 6.48 | 7.16 |
| PEG ratio | 1.90 | 0.01 |
| EV / EBITDA | 10.48 | 12.95 |
| FCF yield | 9.17% | 6.07% |
Profitability
| Metric | BMY | GILD |
|---|---|---|
| Gross margin | 68.75% | 79.35% |
| Operating margin | 25.67% | 38.26% |
| Net margin | 15.01% | 30.99% |
| ROE | 36.25% | 39.19% |
| ROIC | 13.90% | 21.53% |
Dividends
| Metric | BMY | GILD |
|---|---|---|
| Dividend yield | 3.93% | 2.40% |
| Payout ratio | 72.25% | 47.08% |
Growth (annualized)
| Metric | BMY | GILD |
|---|---|---|
| Revenue CAGR (5Y) | 2.52% | 3.07% |
| EPS CAGR (5Y) | 9.38% | 133.83% |
| FCF CAGR (5Y) | -2.50% | 3.30% |
| Total return CAGR (5Y) | 2.58% | 18.12% |
Frequently asked
- Which has the lower trailing P/E, BMY or GILD?
- BMY has the lower trailing P/E: BMY trades at 17.87 and GILD at 18.30. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, BMY or GILD?
- Over the past five years, GILD grew revenue faster — BMY at a 2.52% CAGR versus GILD at 3.07%.
- Does BMY or GILD pay a bigger dividend?
- BMY yields 3.93% and GILD yields 2.40% based on trailing dividends and the latest price.
- Is BMY or GILD more profitable?
- GILD runs the higher net margin — BMY at 15.01% versus GILD at 30.99%.
- How have BMY and GILD total returns compared?
- Over the past 10 years, BMY delivered 1.95% and GILD delivered 8.95% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bristol-Myers Squibb P/E ratioGilead Sciences P/E ratioBristol-Myers Squibb dividend yieldGilead Sciences dividend yieldBristol-Myers Squibb ROEGilead Sciences ROEBristol-Myers Squibb operating marginGilead Sciences operating marginBristol-Myers Squibb revenue growthGilead Sciences revenue growthBristol-Myers Squibb free cash flowGilead Sciences free cash flow
Bristol-Myers Squibb & Gilead Sciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 29, 2026.